Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 1—January 2019
Dispatch

Seroepidemiology of Parechovirus A3 Neutralizing Antibodies, Australia, the Netherlands, and United States

Eveliina Karelehto, Lieke Brouwer, Kimberley Benschop, Jen Kok, Kerri Basile, Brendan McMullan, William Rawlinson, Julian Druce, Suellen Nicholson, Rangaraj Selvarangan, Christopher Harrison, Kamani Lankachandra, Hetty van Eijk, Gerrit Koen, Menno de Jong, Dasja Pajkrt, and Katja C. WolthersComments to Author 
Author affiliations: Academic Medical Center, Amsterdam, the Netherlands (E. Karelehto, L. Brouwer, H. van Eijk, G. Koen, M. de Jong, D. Pajkrt, K.C. Wolthers); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (K. Benschop); Institute of Clinical Pathology and Medical Research, Westmead, New South Wales, Australia (J. Kok, K. Basile); Sydney Children's Hospital, Sydney, New South Wales, Australia (B. McMullan); Prince of Wales Hospital, Randwick, New South Wales, Australia (W. Rawlinson); Doherty Institute, Melbourne, Victoria, Australia (J. Druce, S. Nicholson); Children’s Mercy Hospital, Kansas City, Missouri, USA (R. Selvarangan, C. Harrison); Truman Medical Center, Kansas City (K. Lankachandra)

Main Article

Table 1

Demographic information for study of parechovirus A3 neutralizing antibodies, Australia, the Netherlands, and United States*

Sample group
 Institute
 Sample type
 No. (%) patients
 Patient age, y
Mean
 SD
Country (state) and years
NL 2006–2007 RIVM P 140 (11) 27.8 21.9
NL 2015–2016 AMC R, S 140 (11) 27.8 21.5
USA (MO) 2012–2013 CMH R 120 (9) 30.8 18.3
USA (MO) 2017 CMH, TMC R 171 (13) 25.5 18.8
AUS (VIC) 2011–2012 VIDRL R 138 (11) 26.5 19.9
AUS (VIC) 2015–2016 VIDRL R 138 (11) 26.4 19.6
AUS (NSW) 2011–2012 WH, POW R 185 (14) 26.1 23.2
AUS (NSW) 2015–2016
 WH, POW
 R
 257 (20)
 23.9
 20.6
Sex†
M 598 (46) 25.7 21.3
F
580 (45)
 25.5
 20.5
Age, y
<1 148 (11) 0.4 0.3
1–2 52 (4) 1.8 0.6
3–4 41 (3) 3.8 0.6
5–9 120 (9) 7.2 1.5
10–19 220 (17) 15.8 2.7
20–29 184 (14) 24.8 2.9
30–39 172 (13) 34.2 2.8
40–49 162 (13) 44.6 2.8
50–59 89 (7) 54.8 3.2
60–69 62 (5) 64.3 2.8
>69
38 (3)
 76.4
 5.3
Total 1,288

*AMC, Academic Medical Center; AUS, Australia; CMH, Children’s Mercy Hospital; NL, the Netherlands; P, population-based sampling; POW, Prince of Wales Hospital; R, residual serum from hospitalized patients and community; RIVM, National Institute for Public Health and the Environment; S, AMC staff; SD, standard deviation; TMC, Truman Medical Center; VIC, Victoria; NSW, New South Wales; VIDRL, Victorian Infectious Diseases Reference Laboratory; WH, Westmead Hospital.
†Information on sex not available for US 2017 adult samples.

Main Article

Page created: December 17, 2018
Page updated: December 17, 2018
Page reviewed: December 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external